Highlights

  • Racura Oncology (ASX: RAC) reports that its CPACS Phase 1 trial has cleared the first dose-escalation hurdle, with the Safety Review Committee permitting a step up to 80 mg/m2 of RC220.
  • CPACS uses a Bayesian Optimal Interval (BOIN) design, a modern statistical framework that guides how quickly the trial raises the RC220 dose based on observed safety.
  • The first cohort of three patients received RC220 at 40 mg/m2 with 60 mg/m2 doxorubicin over up to five cycles, with an acceptable safety profile and no dose-limiting toxicities reported.
  • A green light to 80 mg/m2 is a procedural safety decision only, not evidence of efficacy, cardioprotection or survival benefit.
  • CPACS remains an early-stage, open-label Phase 1 study, and investors should weigh substantial clinical, regulatory, funding and commercialisation risks.

For investors following Australian clinical-stage biotechnology, the language of early cancer trials can feel impenetrable. Terms such as dose escalation, BOIN and maximum tolerated combined dose describe the machinery that determines whether a drug candidate advances or stalls. Racura Oncology (ASX: RAC) has given watchers of the stock a fresh reason to understand that machinery. The company has reported that the first patient cohort in its CPACS Phase 1 trial has been reviewed and that dose escalation of its lead formulation, RC220, has been permitted to proceed to the next level of 80 mg/m2. This article unpacks how that decision was reached and why the mechanics matter as much as the headline. Throughout, the focus stays on Racura Oncology and ASX: RAC as an early-stage clinical story rather than a finished one.

Inside the Announcement

According to Racura Oncology, the abstract describing CPACS, titled "Cardioprotection and Anticancer Synergy (CPACS) - A Phase 1 Study of RC220 in Combination with Doxorubicin - Trial in Progress", was accepted for a poster presentation at the Global Cardio-Oncology Summit 2026, to be held in Williamsburg, Virginia, in October 2026. The clinical update carried in that abstract is the substance investors should focus on. The company reports that the first cohort of three patients was treated with RC220 at 40 mg/m2 alongside doxorubicin at 60 mg/m2, over up to five cycles. That cohort was then reviewed by an independent Safety Review Committee (SRC). Racura states that the combination was found to have an acceptable safety profile, with no dose-limiting toxicity or other significant safety concerns observed, and that the SRC allowed escalation to the next RC220 dose level of 80 mg/m2. The company frames these as initial safety findings at the starting dose that support continued dose escalation, with enrolment ongoing. These are clinical observations attributed to the abstract and company.

Background: Racura Oncology and RC220

Racura Oncology Limited is a clinical-stage biopharmaceutical company headquartered in Sydney, describing its mission as an effort to "silence cancer". Its lead asset is (E,E)-bisantrene, a small-molecule anticancer agent understood to work by binding to particular folded structures in DNA and RNA known as G-quadruplexes. By binding these structures, (E,E)-bisantrene is thought to suppress the activity of MYC, or c-MYC, a gene that acts as a master regulator of cancer cell growth. Silencing MYC is the conceptual heart of Racura's approach. RC220 is a proprietary formulation of (E,E)-bisantrene and the compound carried through Racura's clinical programs, including CPACS. It is worth stressing that the MYC-silencing mechanism and the doxorubicin pairing rest heavily on preclinical work. In preclinical models, RC220 combined with doxorubicin showed improved anticancer activity and reduced anthracycline-related cardiac injury, but preclinical results are not clinical proof, and CPACS exists precisely to test whether any of that translates into patients.

How Dose Escalation Actually Works in CPACS

The most useful way to read the CPACS update is to understand the procedure behind the phrase "green light to 80 mg/m2". Dose escalation is the disciplined process by which a Phase 1 trial finds how much of a drug can be given safely.

The safety lead-in and the two-part structure

CPACS is described as a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid tumours. Part 1 is the dose-escalation stage, and Part 2, which follows an interim review, is a dose-expansion cohort. Before the combination is escalated, Part 1 uses monotherapy safety lead-in cycles of each agent. A lead-in means patients are first exposed to the individual drugs on their own, allowing clinicians to characterise how each behaves before the two are combined and pushed to higher doses. This staging is a deliberate caution, separating the safety signal of each drug alone from that of the combination, so any toxicity later observed can be interpreted more clearly.

What the BOIN design does

The escalation itself is guided by a Bayesian Optimal Interval, or BOIN, design. A BOIN design sets a target range around an acceptable toxicity level and, after each cohort, compares the observed rate of serious side effects against that interval. If toxicity sits below the interval, the design supports escalating; if it sits within, staying at the current dose; if it rises above, stepping back down. The appeal for investors is that BOIN is statistically efficient and transparent, with decisions following pre-specified boundaries rather than case-by-case improvisation. In CPACS, RC220 is escalated in combination with a fixed 60 mg/m2 dose of doxorubicin, so the variable being explored is the RC220 dose level.

Dose-limiting toxicity and the Safety Review Committee

The gatekeeping concept in any escalation is the dose-limiting toxicity, or DLT: a pre-defined, serious adverse effect severe enough to cap further dosing. When Racura reports that the first three-patient cohort at 40 mg/m2 recorded no DLTs, it is saying that no patient crossed that pre-defined severity threshold during the assessment window. The independent Safety Review Committee then reviewed the cohort data and permitted the move to 80 mg/m2. That independence matters, because the escalation decision was not made by the company alone. Crucially, a green light to 80 mg/m2 is a safety-based procedural clearance, confirming the lower dose was tolerated well enough to justify testing a higher one. It does not, on its own, say anything about whether RC220 shrinks tumours, protects the heart or extends life.

Where maximum tolerated combined dose fits

The primary objective of Part 1 is the safety and tolerability of the combination. Among the secondary objectives is the maximum tolerated combined dose, abbreviated MTCD, essentially the destination of the escalation journey: the highest combined dose of RC220 and doxorubicin that patients can receive without unacceptable toxicity. Each successful cohort brings the trial closer to defining that ceiling. Other secondary objectives include pharmacokinetics, how the body absorbs and clears the drug, anti-tumour efficacy, and exploratory cardioprotection biomarkers. Part 2 would later examine cardiac-function measures such as GLS, cardiac MRI, LVEF, CTRCD, cardiac biomarkers and VO2 peak, but only after the interim review.

What It Could Mean for ASX: RAC

For ASX: RAC, clearing the first escalation step is a meaningful, if incremental, sign that the CPACS program is progressing as designed. The rationale behind CPACS is notable because anthracyclines such as doxorubicin remain central to many cancer regimens, yet their use is constrained by irreversible cardiotoxicity. Racura's stated aim is to test whether RC220 can be safely combined with doxorubicin to enhance anticancer activity while reducing cardiac injury. Chief Executive Dr Daniel Tillett has said the abstract's acceptance highlights growing interest in RC220's potential to address cardiotoxicity, one of the key limitations of anthracycline-based therapy. Progressing to a higher dose keeps that thesis alive. Investors should nonetheless calibrate expectations. A single cohort of three patients is a very small dataset, and an acceptable early safety profile is the minimum required to continue, not a signal of eventual success.

Limitations and Key Risks

CPACS is an early-stage Phase 1 trial, and the risks are considerable. Clinically, safety is not efficacy: tolerating 40 mg/m2 without dose-limiting toxicity says nothing definitive about whether RC220 will demonstrate anti-tumour activity or protect the heart in humans, and the preclinical cardioprotection and synergy findings are not clinical proof. Higher doses can surface toxicities not seen at lower ones, and escalation to 80 mg/m2 may not be tolerated. Regulatory risk is ever-present, as trial progression, protocol amendments and eventual approvals depend on decisions by health authorities across multiple jurisdictions. Funding risk matters for any clinical-stage biopharmaceutical company, since trials are costly and Racura describes an ambitious pipeline spanning three programs. Execution risk includes patient recruitment across sites in Australia and Hong Kong, with South Korea expected to commence. Commercialisation risk remains distant but real, as even a successful trial must navigate manufacturing, partnering and market access; the company notes it is only exploring partnerships, licensing and merger and acquisition opportunities, with nothing signed. None of these risks should be treated as remote.

What Investors May Watch Next

Several grounded items sit on the near-term horizon for Racura Oncology. The most direct is the poster presentation of the CPACS abstract at the Global Cardio-Oncology Summit in October 2026, which may add detail to the trial-in-progress data. Beyond that, watchers can look for confirmation that the 80 mg/m2 cohort has been enrolled and reviewed, and for the eventual definition of the maximum tolerated combined dose. The commencement of South Korean enrolment, described as expected, would broaden the trial's geographic base. More broadly, Racura has flagged an investor briefing and a near-term catalyst schedule spanning its wider pipeline, including the Phase 3 AML program and the HARNESS-1 Phase 1 study of RC220 with Tagrisso in EGFR-mutant lung cancer. Each is a potential information point rather than a guaranteed positive outcome.

Conclusion

The story behind Racura Oncology's latest CPACS update is less about a single headline number and more about process. By understanding the BOIN design, the safety lead-in, the role of dose-limiting toxicity and the pursuit of a maximum tolerated combined dose, investors in ASX: RAC can read the green light to 80 mg/m2 for exactly what it is: an independent, safety-based decision to keep testing at a higher dose. That is a genuine step forward, yet it remains an early one. Racura Oncology has cleared the first escalation gate, not the finish line, and that difference is where careful investors will keep their attention as CPACS advances.